CLINICAL STUDY OF SURGE OF MUCORMYCOSIS IN COVID-19 PANDEMIC: A TERTIARY CARE CENTER STUDY

ABSTRACT

Background: Mucormycosis is a serious and rare fungal infection that mostly affects the immunocompromised. The symptoms depend on the body part affected or the site of infection. By infecting the nose, sinuses, eye, lungs, and brain, it produces a runny nose, one-sided facial swelling and pain, headache, fever, poor vision, bulging or displacement of the eye (proptosis), and tissue death. Various ailments may cause problems with the skin, stomach and intestines, and lungs. The objective of this research is to assess the prevalence, aetiology, treatment, and prognosis of mucormycosis in post-covid patients at our covid-specific tertiary care hospital. Materials and Methods: A prospective cross-sectional study was conducted on 50 patients admitted to the GGH/Government Medical College's Nizamabad covid department between May 2021 and August 2021 and diagnosed with mucormycosis. Result: The age groups most often affected by mucormycosis ranged from middle-aged to elderly. As a consequence of the ongoing covid pandemic outbreak, few of the affected population, who were mainly diabetic and had a range of hospital presentations, were discovered to have mucormycosis. Covid infection had significant impact on endocrine system as seen by uncontrolled blood glucose levels. The important components of efficient therapy of this condition include early detection, medical care, surgical debridement, proper antifungal medication, and treatment of associated disorders such as diabetes mellitus. Conclusion: Mucormycosis is a rapidly progressing sickness that has been demonstrated to be incurable in late presentation and can cause death;however, early detection and therapy may minimise mortality.